MapLight Therapeutics, Inc. (MPLT) vs Neurogene Inc. (NGNE)
A side-by-side comparison of MapLight Therapeutics, Inc. and Neurogene Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MPLT
MapLight Therapeutics, Inc.
$9.36HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
NGNE
Neurogene Inc.
$26.06HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — MPLT vs NGNE
growth of $100 · dividends reinvested · last 1yMPLT -49.4% (-49.4%/yr)NGNE -17.4% (-17.4%/yr)NGNE compounded faster over this window
MPLT NGNE
MPLT vs NGNE: by the numbers
- •NGNE is the larger company ($412M vs $397M market cap).
Metrics side by side
Valuation
| Metric | MPLT | NGNE |
|---|---|---|
| P/B ratio | 1.14 | 1.90 |
Profitability
| Metric | MPLT | NGNE |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -65.99% | -51.17% |
| ROIC | -69.35% | -54.45% |
Growth (annualized)
| Metric | MPLT | NGNE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -27.73% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.